Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
A Phase I safety study and a Phase II ulcerative colitis trial of the BPC-157 formulation PL 14736 were conducted by the Croatian pharmaceutical company Pliva, but full peer-reviewed Phase II efficacy results have not been published
For temperature-sensitive injectable medications like semaglutide, shipping conditions directly affect potency
BPC-157 has been researched to: Improve healing of many types of wounds Protect intestinal organs and prevents stomach ulcers Combats leaky gut, IBS, gastrointestinal cramps and Crohns disease Accelerate healing of skin burns Work as an anti-inflammatory Maintains integrity of mucosal lining GI tract Repair tissues of GIT, tendons, ligaments, brain, bone, etc
I mean, this becomes medical to me
